U.S. FDA approves Eisai, Biogen's Alzheimer's drug
Jan 6 (Reuters) - The U.S. Food and Drug Administration approved Eisai Co Ltd's and Biogen Inc's Alzheimer's drug lecanemab for patients in the earliest stages of the mind-wasting disease, the agency said on Friday. (Reporting by Deena Beasley in Los Angeles and Bhanvi Satija in Bengaluru; Editing by Bill Berkrot)